- Home
- DHF vs STRO Comparison
DHF vs STRO Comparison
Compare DHF & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- STRO
- Stock Information
- Founded
- DHF 1998
- STRO 2003
- Country
- DHF United States
- STRO United States
- Employees
- DHF N/A
- STRO N/A
- Industry
- DHF Finance Companies
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHF Finance
- STRO Health Care
- Exchange
- DHF Nasdaq
- STRO Nasdaq
- Market Cap
- DHF 172.4M
- STRO 50.0M
- IPO Year
- DHF N/A
- STRO 2018
- Fundamental
- Price
- DHF $2.46
- STRO $0.96
- Analyst Decision
- DHF
- STRO Hold
- Analyst Count
- DHF 0
- STRO 8
- Target Price
- DHF N/A
- STRO $6.14
- AVG Volume (30 Days)
- DHF 451.1K
- STRO 2.4M
- Earning Date
- DHF 01-01-0001
- STRO 05-20-2025
- Dividend Yield
- DHF 7.65%
- STRO N/A
- EPS Growth
- DHF N/A
- STRO N/A
- EPS
- DHF N/A
- STRO N/A
- Revenue
- DHF N/A
- STRO $62,043,000.00
- Revenue This Year
- DHF N/A
- STRO N/A
- Revenue Next Year
- DHF N/A
- STRO $1.29
- P/E Ratio
- DHF N/A
- STRO N/A
- Revenue Growth
- DHF N/A
- STRO N/A
- 52 Week Low
- DHF $2.06
- STRO $0.52
- 52 Week High
- DHF $2.39
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- DHF 51.86
- STRO 52.39
- Support Level
- DHF $2.45
- STRO $0.80
- Resistance Level
- DHF $2.50
- STRO $1.11
- Average True Range (ATR)
- DHF 0.03
- STRO 0.17
- MACD
- DHF 0.01
- STRO 0.03
- Stochastic Oscillator
- DHF 69.23
- STRO 54.91
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.